The SPLASH trial enrolled patients with metastatic castrate-resistant prostate cancer (mCRPC) who progressed on previous treatment with one androgen receptor pathway inhibitor (ARPI) and had a PSMA-avid PET. Of note, patients who received taxane chemotherapy in the castrate-sensitive state were allowed enrollment if the chemotherapy was given more than one year prior to consent. Patients were randomized to Lu-PNT2002, also known as Lu-I&T, at a dose of 6.8 GBq every 8 weeks for up to 4 cycles versus the control arm of an alternate ARPI (enzalutamide or abiraterone). ...
Prostate Cancer
Advertisement
Latest News
The final results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabo/atezo in mCRPC.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
Advertisement
Conference Coverage
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
Dr. Hussain provides his thoughts on how and why to increase worldwide attention on rare forms of bladder cancer.
Dr. Hussain summarizes his presentation on rare and predominant variant histologies in bladder cancer.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Additional evidence for neoadjuvant therapy for patients undergoing RC, ineligible for neoadjuvant platinum-based chemo.
The TiNivo-2 trial found that a tivozanib-nivolumab combination therapy did not improve outcomes over tivozanib alone.
Advertisement
Advertisement
Latest News
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
Dr. Hussain provides his thoughts on how and why to increase worldwide attention on rare forms of bladder cancer.
Dr. Hussain summarizes his presentation on rare and predominant variant histologies in bladder cancer.
